The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal.
暂无分享,去创建一个
[1] I. Sinha,et al. Single-center trials in neonatology: Issues to consider. , 2015, Seminars in fetal & neonatal medicine.
[2] Bingshu E. Chen,et al. Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome. , 2015, European journal of cancer.
[3] N. Thilly,et al. Performing both propensity score and instrumental variable analyses in observational studies often leads to discrepant results: a systematic review. , 2015, Journal of clinical epidemiology.
[4] V. Prasad,et al. The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses. , 2015, JAMA internal medicine.
[5] M. Jit,et al. Discounting in the evaluation of the cost-effectiveness of a vaccination programme: A critical review. , 2015, Vaccine.
[6] D. Husereau. How do we value a cure? , 2015, Expert review of pharmacoeconomics & outcomes research.
[7] M. Buyse,et al. Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer. , 2015, Journal of clinical epidemiology.
[8] David L Porter,et al. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. , 2015, Blood.
[9] F. Chun,et al. Prognostic, predictive and potential surrogate markers in castration-resistant prostate cancer , 2015, Expert review of anticancer therapy.
[10] M. Morsy,et al. Demographic Transition, Health Care Challenges, and the Impact of Emerging International Regulatory Trends With Relevance to Regenerative Medicine , 2015, Current Stem Cell Reports.
[11] M. Sadelain,et al. Efficacy and safety of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed or refractory B-ALL. , 2015 .
[12] S. Xie,et al. Assessing treatment effects with surrogate survival outcomes using an internal validation subsample , 2015, Clinical trials.
[13] R. Bassan,et al. Minimal Residual Disease Monitoring in Adult ALL to Determine Therapy , 2015, Current Hematologic Malignancy Reports.
[14] S. Pauker,et al. Using nonrandomized studies to inform complex clinical decisions: The thorny issue of cranial radiation therapy for T‐cell acute lymphoblastic leukemia , 2015, Pediatric blood & cancer.
[15] P. Kebriaei,et al. Future of Therapy in Acute Lymphoblastic Leukemia (ALL)—Potential Role of Immune-Based Therapies , 2015, Current Hematologic Malignancy Reports.
[16] V. Sambucini. Comparison of Single-Arm vs. Randomized Phase II Clinical Trials: A Bayesian Approach , 2015, Journal of biopharmaceutical statistics.
[17] D. Sipp. Conditional approval: Japan lowers the bar for regenerative medicine products. , 2015, Cell stem cell.
[18] A. Borkhardt,et al. Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment , 2015, Leukemia.
[19] Christian Ohmann,et al. Combining randomized and non‐randomized evidence in clinical research: a review of methods and applications , 2015, Research synthesis methods.
[20] S. Steinberg,et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial , 2015, The Lancet.
[21] B. Levine. Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells , 2015, Cancer Gene Therapy.
[22] D. Teachey,et al. T Cells Engineered with a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children with Relapsed, Refractory ALL , 2014 .
[23] J. Woodcock,et al. Accelerated Access to Innovative Medicines for Patients in Need , 2014, Clinical pharmacology and therapeutics.
[24] Pamela A Shaw,et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.
[25] D. Teachey,et al. Abstract PR06: T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) produce complete responses and long-term persistence without GVHD in children with relapsed, refractory ALL , 2014 .
[26] J. Hoekman,et al. The Use of Surrogate Endpoints in Regulating Medicines for Cardio-Renal Disease: Opinions of Stakeholders , 2014, PloS one.
[27] S. Doi. Evidence Synthesis for Medical Decision Making and the Appropriate Use of Quality Scores , 2014, Clinical Medicine & Research.
[28] J. Crowley,et al. Historical controls for metastatic pancreatic cancer: benchmarks for planning and analyzing single-arm phase II trials. , 2014, Clinical cancer research : an official journal of the American Association for Cancer Research.
[29] J. Fuster,et al. Current approach to relapsed acute lymphoblastic leukemia in children , 2014 .
[30] S. Gottlieb,et al. Establishing New Payment Provisions for the High Cost of Curing Disease , 2014 .
[31] Christopher McCabe,et al. Sharing risk between payer and provider by leasing health technologies: an affordable and effective reimbursement strategy for innovative technologies? , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[32] J. Paulus,et al. Opportunities and challenges in using studies without a control group in comparative effectiveness reviews , 2014, Research synthesis methods.
[33] K. Curran,et al. Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies , 2014, International Journal of Hematology.
[34] J. Radich,et al. Impact of Minimal Residual Disease, Detected by Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia , 2014, Leukemia research and treatment.
[35] Qing He,et al. Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.
[36] Nicky J Welton,et al. Treatment comparisons for decision making: facing the problems of sparse and few data , 2014 .
[37] J. Thompson,et al. Use of Bayesian Multivariate Meta-Analysis to Estimate the HAQ for Mapping Onto the EQ-5D Questionnaire in Rheumatoid Arthritis , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[38] L. Trinquart,et al. Comparison of Treatment Effect Estimates From Prospective Nonrandomized Studies With Propensity Score Analysis and Randomized Controlled Trials of Surgical Procedures , 2014, Annals of surgery.
[39] M. Buyse,et al. VALIDATION OF SURROGATE ENDPOINTS IN ADVANCED SOLID TUMORS: SYSTEMATIC REVIEW OF STATISTICAL METHODS, RESULTS, AND IMPLICATIONS FOR POLICY MAKERS , 2013, International Journal of Technology Assessment in Health Care.
[40] F. Wood,et al. Does the type of skin replacement surgery influence the rate of infection in acute burn injured patients? , 2013, Burns : journal of the International Society for Burn Injuries.
[41] R. Prondzinsky,et al. Single-center trials tend to provide larger treatment effects than multicenter trials: a systematic review. , 2013, Journal of clinical epidemiology.
[42] H. Martin,et al. Complete cytogenetic response and major molecular response as surrogate outcomes for overall survival in first-line treatment of chronic myelogenous leukemia: a case study for technology appraisal on the basis of surrogate outcomes evidence. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[43] S. Golder,et al. Comparison of Pooled Risk Estimates for Adverse Effects from Different Observational Study Designs: Methodological Overview , 2013, PloS one.
[44] B. Meister,et al. Outcome of Children and Adolescents With a Second or Third Relapse of Acute Lymphoblastic Leukemia (ALL): A Population-based Analysis of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) Study Group , 2013, Journal of pediatric hematology/oncology.
[45] D. Campana,et al. Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation , 2013, British journal of haematology.
[46] F. Appelbaum,et al. Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia , 2013, Bone Marrow Transplantation.
[47] B. Kramer,et al. Surrogate endpoint analysis: an exercise in extrapolation. , 2013, Journal of the National Cancer Institute.
[48] O. Ciani,et al. Surrogate, friend or foe? The need for case studies of the use of surrogate outcomes in cost-effectiveness analyses. , 2013, Health economics.
[49] J. Sterne,et al. Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta-epidemiological study , 2013, BMJ.
[50] N. Latimer. Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.
[51] P. Kawalec,et al. Economic evaluation of acute lymphoblastic leukemia treatment with clofarabine (Evoltra) combined with chemotherapy for children and adolscents in Poland , 2012, Journal of Health Policy & Outcomes Research.
[52] T. Trikalinos,et al. Do observational studies using propensity score methods agree with randomized trials? A systematic comparison of studies on acute coronary syndromes. , 2012, European heart journal.
[53] Asha B. Pillai,et al. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. , 2012, Blood.
[54] Anne Rogers,et al. Surrogates, meta-analysis and cost-effectiveness modelling: a combined analytic approach. , 2012, Health economics.
[55] Karl Claxton,et al. Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[56] P. Rothwell,et al. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. , 2012, The Lancet. Oncology.
[57] M. Postma,et al. On discounting of health gains from human papillomavirus vaccination: effects of different approaches. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[58] S. Sleijfer,et al. The challenge of choosing appropriate end points in single-arm phase II studies of rare diseases. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] Nicky J Welton,et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves , 2012, BMC Medical Research Methodology.
[60] H. Einsele,et al. Anti-CD19 BiTE Blinatumomab Induces High Complete Remission Rate In Adult Patients with Relapsed B-Precursor ALL: Updated Results of An Ongoing Phase II Trial , 2011 .
[61] G. Tomlinson,et al. A framework for applying unfamiliar trial designs in studies of rare diseases. , 2011, Journal of clinical epidemiology.
[62] Pierfrancesco Agostoni,et al. Are propensity scores really superior to standard multivariable analysis? , 2011, Contemporary clinical trials.
[63] P. Austin. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies , 2011, Multivariate behavioral research.
[64] G. Pond,et al. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials , 2011, Clinical trials.
[65] David J. Spiegelhalter,et al. Development of a Transparent Interactive Decision Interrogator to Facilitate the Decision-Making Process in Health Care , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[66] H. Kantarjian,et al. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration , 2010, Cancer.
[67] S. Unal,et al. FLUDARABINE, CYTARABINE, GRANULOCYTE COLONY-STIMULATING FACTOR, AND IDARUBICIN (FLAG-IDA) FOR THE TREATMENT OF CHILDREN WITH POOR-PROGNOSIS ACUTE LEUKEMIA: The Hacettepe Experience , 2010, Pediatric hematology and oncology.
[68] A. Huston,et al. A tale of two methods: comparing regression and instrumental variables estimates of the effects of preschool child care type on the subsequent externalizing behavior of children in low-income families. , 2010, Developmental psychology.
[69] P. Gøtzsche,et al. Inconsistent reporting of surrogate outcomes in randomised clinical trials: cohort study , 2010, BMJ : British Medical Journal.
[70] C. Palacio,et al. Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia , 2010, Haematologica.
[71] M. Tormo,et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group , 2010, Haematologica.
[72] M. Loh,et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[73] R. Kurzrock,et al. Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[74] R. Bellomo,et al. Why we should be wary of single-center trials , 2009, Critical care medicine.
[75] D. Sargent,et al. Excessive false-positive errors in single-arm phase II trials: A simulation-based analysis. , 2009, Journal of Clinical Oncology.
[76] Jeremy MG Taylor,et al. Current Issues in Oncology Drug Development, with a Focus on Phase II Trials , 2009, Journal of biopharmaceutical statistics.
[77] P. Austin. The International Journal of Biostatistics Type I Error Rates , Coverage of Confidence Intervals , and Variance Estimation in Propensity-Score Matched Analyses , 2011 .
[78] Simon G Thompson,et al. Accounting for uncertainty in health economic decision models by using model averaging , 2009, Journal of the Royal Statistical Society. Series A,.
[79] J. Elston,et al. Use of surrogate outcomes in cost-effectiveness models: A review of United Kingdom health technology assessment reports1 , 2009, International Journal of Technology Assessment in Health Care.
[80] David J Spiegelhalter,et al. Bias modelling in evidence synthesis , 2009, Journal of the Royal Statistical Society. Series A,.
[81] Douglas G. Altman,et al. Models for potentially biased evidence in meta‐analysis using empirically based priors , 2009 .
[82] H. Kantarjian,et al. Outcome of adults with acute lymphocytic leukemia after second salvage therapy , 2008, Cancer.
[83] Anthonius de Boer,et al. Systematic differences in treatment effect estimates between propensity score methods and logistic regression. , 2008, International journal of epidemiology.
[84] H. Kiene,et al. Combined bias suppression in single-arm therapy studies , 2008, Journal of evaluation in clinical practice.
[85] M. Loh,et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study , 2008, Leukemia.
[86] L. Robison,et al. Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. , 2008, Blood.
[87] Donna Niedzwiecki,et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[88] B. De Angelis,et al. A randomized trial comparing ReCell system of epidermal cells delivery versus classic skin grafts for the treatment of deep partial thickness burns. , 2007, Burns : journal of the International Society for Burn Injuries.
[89] D. Sargent,et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[90] S. Richardson,et al. Hierarchical related regression for combining aggregate and individual data in studies of socio‐economic disease risk factors , 2007 .
[91] H. Dombret,et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial , 2007, Leukemia.
[92] J. Brophy,et al. The cost-effectiveness of stem cell transplantations from unrelated donors in adult patients with acute leukemia. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[93] Paul W Dickman,et al. Estimating and modeling the cure fraction in population-based cancer survival analysis. , 2007, Biostatistics.
[94] R. Gralla,et al. Comparing two methods of meta-analysis in clinical research - individual patient data-based (IPD) and literature-based abstracted data (AD) methods: Analyzing five oncology issues involving more than 10,000 patients in randomized clinical trials (RCTs) , 2007 .
[95] J. Spinelli,et al. Mortality among 5‐year survivors of cancer diagnosed during childhood or adolescence in British Columbia, Canada , 2007, Pediatric blood & cancer.
[96] P. Tugwell,et al. Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. , 2007, The Journal of rheumatology.
[97] Peter C Austin,et al. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study , 2007, Statistics in medicine.
[98] Andrew J Vickers,et al. Setting the Bar in Phase II Trials: The Use of Historical Data for Determining “Go/No Go” Decision for Definitive Phase III Testing , 2007, Clinical Cancer Research.
[99] Rajesh Chopra,et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. , 2007, Blood.
[100] Elliott S Fisher,et al. Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. , 2007, JAMA.
[101] G. Gustafsson,et al. Pathways through relapses and deaths of children with acute lymphoblastic leukemia: role of allogeneic stem-cell transplantation in Nordic data. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[102] Jane M. Young,et al. How Does an Historic Control Study of a Surgical Procedure Compare With the “Gold Standard”? , 2006, Diseases of the colon and rectum.
[103] Sylvia Richardson,et al. Improving ecological inference using individual‐level data , 2006, Statistics in medicine.
[104] Peter C Austin,et al. A comparison of propensity score methods: a case‐study estimating the effectiveness of post‐AMI statin use , 2006, Statistics in medicine.
[105] Til Stürmer,et al. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. , 2006, Journal of clinical epidemiology.
[106] R. Arceci,et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[107] J. Robins,et al. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. , 2006, American journal of epidemiology.
[108] R. McNamee,et al. Regression modelling and other methods to control confounding , 2005, Occupational and Environmental Medicine.
[109] Peter C Austin,et al. Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review. , 2005, Journal of clinical epidemiology.
[110] J. Lunceford,et al. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study , 2004, Statistics in medicine.
[111] Vance W Berger,et al. Does the Prentice criterion validate surrogate endpoints? , 2004, Statistics in medicine.
[112] R. Katz,et al. Biomarkers and surrogate markers: An FDA perspective , 2004, NeuroRX.
[113] N. G. Best,et al. Bayesian approaches to multiple sources of evidence and uncertainty in complex cost‐effectiveness modelling , 2003, Statistics in medicine.
[114] M Soledad Cepeda,et al. Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. , 2003, American journal of epidemiology.
[115] Sunil J Rao,et al. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2003 .
[116] A. Detsky,et al. Treatment options for patients with acute myeloid leukemia with a matched sibling donor , 2003, Cancer.
[117] P. Royston,et al. Flexible parametric proportional‐hazards and proportional‐odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects , 2002, Statistics in medicine.
[118] A. Hanks. Canada , 2002 .
[119] R. Holloway,et al. Clinical trial end points: on the road to nowhere? , 2002, Neurology.
[120] J. Ioannidis,et al. Comparison of evidence of treatment effects in randomized and nonrandomized studies. , 2001, JAMA.
[121] David R. Jones,et al. Hierarchical models in generalized synthesis of evidence: an example based on studies of breast cancer screening. , 2000, Statistics in medicine.
[122] A. Hartz,et al. A comparison of observational studies and randomized, controlled trials. , 2000, The New England journal of medicine.
[123] J. Concato,et al. Randomized, controlled trials, observational studies, and the hierarchy of research designs. , 2000, The New England journal of medicine.
[124] Terry L. Smith,et al. Primary refractory and relapsed adult acute lymphoblastic leukemia , 1999, Cancer.
[125] G. Guyatt,et al. Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group. , 1999, JAMA.
[126] J. V. Stone,et al. Long-Term Survival and Late Deaths after Allogeneic Bone Marrow Transplantation , 1999 .
[127] J. Hewison,et al. Ethical issues in the design and conduct of randomised controlled trials. , 1998, Health technology assessment.
[128] M J Campbell,et al. Choosing between randomised and non-randomised studies: a systematic review , 1998, BMJ.
[129] G. Molenberghs,et al. Criteria for the validation of surrogate endpoints in randomized experiments. , 1998, Biometrics.
[130] T. Fleming,et al. Perspective: validating surrogate markers--are we being naive? , 1997, The Journal of infectious diseases.
[131] M. Drummond,et al. The Iterative Use of Economic Evaluation as Part of the Process of Health Technology Assessment , 1997, Journal of health services research & policy.
[132] D. DeMets,et al. Surrogate End Points in Clinical Trials: Are We Being Misled? , 1996, Annals of Internal Medicine.
[133] V Torri,et al. Beware of Surrogate Outcome Measures , 1996, International Journal of Technology Assessment in Health Care.
[134] D G Altman,et al. Statistics notes: Matching , 1994 .
[135] M S Pepe,et al. Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research. , 1994, Statistics in medicine.
[136] S. Ellenberg. Surrogate endpoints. , 1993, British Journal of Cancer.
[137] E. Chelimsky,et al. Cross-design Synthesis: A New Form of Meta-analysis for Combining Results from Randomized Clinical Trials and Medical-practice Databases , 1993, International Journal of Technology Assessment in Health Care.
[138] S. Ellenberg,et al. Surrogate endpoints in clinical trials: cancer. , 1989, Statistics in medicine.
[139] R. Prentice. Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.
[140] J. Herson. The use of surrogate endpoints in clinical trials (an introduction to a series of four papers) , 1989 .
[141] Gavin Mooney,et al. Economics, medicine, and health care , 1987 .
[142] T C Chalmers,et al. Randomized versus historical controls for clinical trials. , 1982, The American journal of medicine.
[143] Katherine Karakasis,et al. Outcomes and endpoints in trials of cancer treatment: the past, present, and future. , 2015, The Lancet. Oncology.
[144] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[145] K Claxton,et al. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development. , 2012, Health technology assessment.
[146] J. Stockman. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial , 2012 .
[147] D. Mortimer. Modelling Downstream Effects in the Presence of Technological Change , 2012, PharmacoEconomics.
[148] P. Tappenden,et al. A Review of Studies Examining the Relationship between Progression-Free Survival and Overall Survival in Advanced or Metastatic Cancer , 2012 .
[149] R. Arceci. Outcomes after Induction Failure in Childhood Acute Lymphoblastic Leukemia , 2012 .
[150] G. Henze,et al. Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: a retrospective analysis of the ALL-REZ BFM Study Group. , 2011, European journal of cancer.
[151] Mark Sculpher,et al. REPORT BY THE DECISION SUPPORT UNIT , 2010 .
[152] J. Elston,et al. The use of surrogate outcomes in model-based cost-effectiveness analyses: a survey of UK Health Technology Assessment reports. , 2009, Health technology assessment.
[153] R. Arceci,et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study , 2009 .
[154] C. Mason,et al. A brief definition of regenerative medicine. , 2008, Regenerative medicine.
[155] D. Torgerson,et al. Designing randomised trials in health, education and the social sciences : an introduction , 2008 .
[156] D. Lanska,et al. Assessing observational studies of medical treatments , 2005, Emerging themes in epidemiology.
[157] 農林水産奨励会農林水産政策情報センター,et al. The green book : appraisal and evaluation in central government , 2003 .
[158] A. Hagenbeek,et al. Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia , 2002, Bone Marrow Transplantation.
[159] T A Sheldon,et al. A systematic review of comparisons of effect sizes derived from randomised and non-randomised studies. , 2000, Health technology assessment.
[160] D. Chadwick,et al. Implications of socio-cultural contexts for the ethics of clinical trials. , 1997, Health technology assessment.
[161] B. Graubard,et al. Statistical validation of intermediate endpoints for chronic diseases. , 1992, Statistics in medicine.
[162] P. Woodhead. Medicines Adaptive Pathways to Patients ( MAPPs ) – Opportunities and Challenges in Europe , 2022 .